Navigation Links
Former GE Healthcare Director, Per Foss Appointed CEO for HUNT Biosciences
Date:4/23/2009

LEVANGER, Norway, April 23 /PRNewswire/ -- HUNT Biosciences, the commercial arm of the HUNT Study and associated biobank today announced the appointment of former GE Healthcare director Per Foss as its new CEO. The company provides pharmaceutical and healthcare companies with biomarker discovery and validation services. These are based on the unique HUNT Study, which for the past 25 years has gathered blood samples from the general population of the Nord-Trondelag region together with detailed phenotype and environmental data. Foss joins just as recruitment for the third phase, HUNT III has closed, again with an astonishing high inclusion rate of 60%. This will bring the total recruitment number of unique individuals to 135,000 and reinforce the core strengths in key public health areas such as cancer, cardiovascular disease, diabetes, obstructive lung disease, osteoporosis and mental health. More than 60 % of the participants have been screened twice, 25 % have participated in all three surveys.

"For both pharmaceutical and biotech companies, HUNT Biosciences is ideally positioned to devise biomarker strategies across a wide range of key disease areas," says Foss. "The unique combination of biomedical and phenotypic information collected over the past 25 years from a general population rather than specific cohort promises rapid and effective biomarker discovery and validation."

The HUNT Study operates as a satellite to the Norwegian University of Science and Technology (NTNU) . Per Ivar Maudal, Executive Director for innovation and industrial relations at NTNU and chairman of the board of HUNT Biosciences, welcomes the appointment: "For academic researchers HUNT already provides data on a large number of diseases observed in this general population. It has been validated by more than 45 completed PhD-degrees and several hundred ongoing or completed research projects with particular emphasis on major di
'/>"/>

SOURCE HUNT Biosciences
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Pepscan Achieves a Breakthrough With CLIPS Immunogen Technology: Synthetic Peptide Antigen is Able to Induce Fully Functional Antibodies Against a Formerly Intractable GPCR Target CXCR7
2. Lakewood-Amedex, Inc. Appoints William J. Robison, Former Executive Vice President of Pfizer, as Board Member
3. Former President of Sports Cardiology Consultants, LLC Christine Lawless, MD, MBA, ABCL, FACC, FACSM, Named Medical Director of CME Enterprise
4. Micromet Adds Former Head of Roche Oncology Kapil Dhingra, MD to Board of Directors
5. Former SADMERC Medical Directors Join OrthoCare Innovations as Medical and Scientific Advisory Board Members and Strategic Advisors
6. Cyntellect Appoints Former Millipore and BD Biosciences Executives to Head Up its Product Marketing Efforts
7. Cyntellect Appoints Former BD Biosciences Executive Andre Lubarsky as Director of Sales - North America
8. Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer
9. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
10. Former NASDAQ International President Among Execs Launching Firm to Access Global Markets
11. Shire Successfully Settles Former TKT Shareholder Appraisal Rights Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2015)... A leading manufacturer of stainless steel tanks and ... custom fabrication services today at INTERPHEX 2015. The company ... prior to the INTERPHEX event. The expo takes place ... at the Javits Center in New York City, where ... most innovative pharmaceutical and biotech firms will be in ...
(Date:4/20/2015)... -- Stent retriever thrombectomy, an endovascular technique that ... reduced disability after stroke, according to a groundbreaking ... the Society of Vascular and Interventional Neurology (SVIN).  ... forward that will change the way we approach ... who is associate professor of Neurology and Neurosurgery ...
(Date:4/20/2015)... April 20, 2015 Orthobiologics are ... bone injuries. The orthobiologics market is a rewarding market, ... stakeholders. The global orthobiologics market report defines and segments ... The global orthobiologics market was valued at $5,712.4 million ... by 2019, at a CAGR of 6.7% from 2014 ...
(Date:4/20/2015)... INDIANAPOLIS , April 20, 2015  Eli Lilly ... stage data from several targeted cancer therapies, reflecting Lilly,s ... Research (AACR) Annual Meeting 2015, held April 18-22 in ... "Bringing Cancer Discoveries to Patients" is the theme of ... through Lilly,s commitment to broadening its portfolio of therapies ...
Breaking Biology Technology:HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 2HOLLOWAY AMERICA to Reveal Newly Designed Responsive Website at INTERPHEX 2015 Today 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 2Global Orthobiologics Market is Expected to Reach $7,900.2 Million by 2019, at a CAGR of 6.7% from 2014 to 2019 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 2Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 3Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 4Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 5Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015 6
... - Conference Call to Discuss Results to Be Held at ... Incorporated,s (Nasdaq: VPHM ) first quarter financial results ... 29, 2009 before the open of the U.S. financial markets.The ... at 9:00 a.m. Eastern Time on the same day. ...
... Human Tissue Collection and Specimen Management Provide FocusMEMPHIS, ... the physician partners of Accelerated Community Oncology Research ... (USA), has begun acquiring human tissue samples for ... World BioBank supports biomarker storage in conjunction with ...
... Calif., April 22 Metabolex, Inc., a biopharmaceutical company ... therapeutics for the treatment of diabetes and related metabolic ... to its Board of Directors. Mr. von Emster currently ... November 2000 to March 2009, Mr. von Emster was ...
Cached Biology Technology:ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2World BioBank(TM) Launch Benefits Advanced Medical Research 2World BioBank(TM) Launch Benefits Advanced Medical Research 3Metabolex Announces Election of Kurt von Emster to Board of Directors 2
(Date:4/2/2015)... GOTHENBURG, Sweden , April 2, 2015 ... revenues for Q1 2015 attributed to somewhat higher than ... company in the year-end report 2014 that revenues for ... MSEK that the company reported for Q4 2014. The ... continue to be negative. The complete interim report will ...
(Date:4/1/2015)... Medisafe ™, the leading global medication management platform with ... Android smartphones and tablets, announces today that ... allow patients to track and correlate their adherence directly ... be able to visualize in real-time how taking medication ... glucose levels and blood pressure. "Patients need ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... that freezing kidney tumors through percutaneous cryoablation shows promise ... Their early findings showing short-term success in more ... this month’s issue of Radiology. , The standard treatment ... of a long-term cure. For some patients, surgery ...
... Medicine has helped confirm the reliability of a new ... long-promised era of personalized medicine based on each individual's ... five sites that helped determine that the genetic test ... developing cirrhosis from chronic hepatitis C infection. That means ...
... A study of eight hospitals in Peru has shown ... double that of mechanically ventilated negative-pressure rooms and 18 ... , The researchers, led by Rod Escombe from ... ventilated clinical rooms such as respiratory isolation rooms, TB ...
Cached Biology News:Cryoablation -- A new treatment option for some kidney tumor patients 2Cryoablation -- A new treatment option for some kidney tumor patients 3New test helps identify hepatitis C patients at high risk of developing cirrhosis 2New test helps identify hepatitis C patients at high risk of developing cirrhosis 3
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Mouse monoclonal [RIZ1723] to PRDM2/RIZ...
MagSi uniform silica particles coated with a carboxyl group containing polymer, covalently attached to the bead surface....
Mouse monoclonal [1241] to Parainfluenza Virus type 2...
Biology Products: